Greenwind Holdings Inc. (NEWG) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerGreenwind Holdings Inc. (NEWG) trades at $0.0001. Greenwind Holdings Inc. is a development-stage company focused on identifying and acquiring investment opportunities within the healthcare sector. The company, formerly NewGen BioPharma Corp., is based in Seattle, Washington. Sector: Financials.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for NEWG: NEWG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Greenwind Holdings Inc. (NEWG) Financial Services Profile
Greenwind Holdings Inc., operating in the medical pharmaceuticals industry, is a development-stage company seeking investment opportunities. Formerly NewGen BioPharma Corp., the company is based in Seattle and currently has a negative P/E ratio, reflecting its development stage and focus on future acquisitions.
What Is the Investment Thesis for NEWG?
Greenwind Holdings Inc. presents a speculative investment opportunity, primarily due to its status as a development-stage company. The company's strategy revolves around acquiring investment opportunities, primarily in the healthcare sector. The company's current market capitalization is $0.00B, and it has a negative P/E ratio of -0.11, reflecting its current lack of profitability. A key risk is the company's OTC listing and associated shell risk, requiring careful due diligence. Potential catalysts include successful acquisitions and subsequent value creation. The company's high beta of -44.71 suggests extreme volatility relative to the market.
Based on FMP financials and quantitative analysis
NEWG Key Highlights
Development-stage company focused on acquiring investment opportunities.
- Operates within the Medical - Pharmaceuticals industry.
- Formerly known as NewGen BioPharma Corp., rebranded in April 2017.
- Market Cap of $0.00B indicates a micro-cap company.
- Negative P/E ratio of -0.11 reflects a lack of current profitability.
Who Are NEWG's Competitors?
NEWG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CIIT Tianci International, Inc. | $2.51 | +1.21% | 32 5-pillar | |
| COLA Columbus Acquisition Corp | $2.86 | -60.82% | $12.9M | 44 5-pillar |
| ASPC A SPAC III Acquisition Corp. | $10.81 | -0.16% | $25.3M | 47 5-pillar |
| RIBB Ribbon Acquisition Corp | $7.26 | -8.73% | $36.2M | 42 5-pillar |
| BKHA Black Hawk Acquisition Corporation | $12.20 | -1.45% | $51.4M | 47 5-pillar |
| IBAC IB Acquisition Corp. | $10.88 | -0.18% | $54.6M | 43 5-pillar |
| FVN Future Vision II Acquisition Corp. | $8.40 | +4.93% | $60.4M | 42 5-pillar |
| APAC StoneBridge Acquisition Corporation | $10.28 | +0.10% | $63.0M | 50 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NEWG's Key Strengths?
Focus on the high-growth healthcare sector.
- Experienced management team with investment expertise.
- Flexibility to invest in various healthcare sub-sectors.
- Potential for high returns through successful acquisitions.
What Are NEWG's Weaknesses?
Development-stage company with limited operating history.
- Reliance on external funding for acquisitions.
- High risk associated with early-stage investments.
- Limited revenue generation in the current stage.
What Are the Key Risks for NEWG?
Financial-distress signal — its Altman Z-Score of -5.60 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to identify and acquire suitable investment opportunities.
- Limited financial resources and reliance on external funding.
- High competition in the healthcare investment landscape.
- Regulatory changes impacting the healthcare sector.
- Economic downturn affecting investment valuations.
What Threats Does NEWG Face?
- Intense competition in the healthcare sector.
- Regulatory hurdles and compliance requirements.
- Economic downturn impacting investment activity.
- Risk of unsuccessful acquisitions or investments.
What Are NEWG's Competitive Advantages?
- Proprietary deal flow through industry connections.
- Expertise in evaluating healthcare investment opportunities.
- Access to capital for strategic acquisitions.
- Ability to provide value-added support to portfolio companies.
What Does NEWG Do?
Greenwind Holdings Inc., established in 2010 and headquartered in Seattle, Washington, operates as a development-stage company primarily focused on identifying and acquiring investment opportunities. Originally founded as NewGen BioPharma Corp., the company rebranded to Greenwind Holdings Inc. in April 2017, signaling a shift in its strategic direction. The company's core business model revolves around seeking out prospective ventures, primarily within the healthcare sector, with the aim of fostering growth and generating returns through strategic investments. As a development-stage entity, Greenwind Holdings Inc. is actively involved in evaluating potential acquisitions and partnerships. The company's activities are centered around the pharmaceutical and medical sectors, indicating a focus on companies involved in drug development, medical devices, or related healthcare technologies. Greenwind Holdings Inc. is still in the early stages of its development, and its success depends on its ability to identify and capitalize on promising investment opportunities.
What Products and Services Does NEWG Offer?
- Identifies and evaluates potential investment opportunities.
- Focuses on companies within the healthcare sector.
- Targets businesses involved in pharmaceuticals and medical technologies.
- Seeks to acquire or partner with promising ventures.
- Aims to generate returns through strategic investments.
- Operates as a development-stage company.
How Does NEWG Make Money?
- Acquires equity stakes in target companies.
- Provides capital and resources to support growth.
- Monetizes investments through strategic exits.
- Focuses on long-term value creation.
What Industry Does NEWG Operate In?
Greenwind Holdings Inc. operates within the medical pharmaceuticals industry, a sector characterized by high research and development costs, stringent regulatory requirements, and significant growth potential. The industry is driven by factors such as an aging global population, increasing prevalence of chronic diseases, and technological advancements in drug discovery and delivery. Greenwind's strategy of acquiring investment opportunities positions it within the broader trend of consolidation and strategic partnerships within the pharmaceutical landscape. Competitors include companies like COTQF, DMSI, GGBXF, IBXG, and LFPI, each pursuing different strategies within the sector.
Who Are NEWG's Key Customers?
- Target companies seeking capital and expertise.
- Investors seeking exposure to the healthcare sector.
- Potential acquirers of Greenwind's portfolio companies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Greenwind Holdings Inc. operates in the Financial Services sector. It is headquartered in Seattle, US. The company is led by CEO Bradford James Long. NEWG has traded publicly since 2022.
Financial Health
Greenwind Holdings Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.60 places it in the distress zone, a signal of elevated financial risk.
NEWG Financials
NEWG Latest News
No recent news available for NEWG.
NEWG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NEWG.
Price Targets
Wall Street price target analysis for NEWG.
NEWG MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NEWG; grades run from A+ (80-100) to F (below 30).
Leadership: Bradford James Long
CEO
Bradford James Long serves as the Chief Executive Officer of Greenwind Holdings Inc. His professional background includes experience in corporate management and strategic development, with a focus on identifying and executing investment opportunities. Long's expertise lies in guiding early-stage companies through periods of growth and transformation. His leadership is centered on building shareholder value through strategic acquisitions and partnerships. He brings a wealth of knowledge in navigating the complexities of the healthcare sector and driving innovation.
Track Record: Under Bradford James Long's leadership, Greenwind Holdings Inc. has focused on identifying and evaluating potential acquisition targets within the healthcare industry. Key strategic decisions have involved restructuring the company's focus towards investment opportunities and rebranding from NewGen BioPharma Corp. While specific milestones are limited due to the company's development stage, Long's tenure has been marked by efforts to position Greenwind for future growth through strategic investments.
NEWG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Greenwind Holdings Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and trading activity may be thin. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, leading to increased risks for investors. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads create liquidity risk.
- Potential for price manipulation due to lack of regulatory oversight.
- Higher risk of fraud or mismanagement compared to listed companies.
- Shell risk detected, indicating potential for illicit activities.
- Verify the company's legal standing and registration.
- Review available financial statements and disclosures.
- Assess the company's business model and revenue generation.
- Investigate the background and experience of the management team.
- Evaluate the company's competitive landscape and market position.
- Check for any regulatory filings or legal proceedings.
- Consult with a qualified financial advisor.
- Clear business plan and defined target market.
- Experienced management team with relevant industry expertise.
- Independent audits of financial statements (if available).
- Positive media coverage or industry recognition.
- Active engagement with investors and stakeholders.
Greenwind Holdings Inc. Financials Stock: Key Questions Answered
What do analysts say about NEWG stock?
As of March 17, 2026, there is no available analyst coverage for Greenwind Holdings Inc. (NEWG). Given its status as an OTC-listed, development-stage company with a market capitalization of $0.00B, the lack of analyst coverage is not unexpected. Investors should conduct their own thorough due diligence and consider the inherent risks associated with investing in micro-cap, OTC stocks.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available sources and may be limited due to the company's development stage and OTC listing.